NasdaqGS:SVRABiotechs
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported second-quarter 2026 results showing a net loss of US$40.23 million and a wider per-share loss, while also filing a US$108.30 million shelf registration for up to 18,900,000 common shares tied to an ESOP-related offering.
The company highlighted clear regulatory timelines for its lead therapy MOLBREEVI, with U.S. and European decisions scheduled through late 2026 and early 2027, underscoring how closely its outlook is tied to upcoming approval outcomes.
Next, we’ll...